Sustained Effectiveness of mRNA Vaccines Against COVID-19 Hospitalizations Save
The CDC has reported that mRNA vaccine effectiveness against COVID-19–associated hospitalizations was sustained over 24 weeks; but there is evidence of waning protection amongst the immunosuppressed.
They studied vaccine responses among 1,129 patients who received 2 doses of a mRNA vaccine, no decline in vaccine effectiveness against COVID-19 hospitalization was observed over 24 weeks. Vaccine effectiveness was 86% 2–12 weeks after vaccination and 84% at 13–24 weeks. Vaccine effectiveness was sustained among groups at risk for severe COVID-19.
This real-world study from 21 US hospitals included 3,089 mRNA vaccinated, hospitalized adults (including 1,194 COVID-19 case-patients and 1,895 non–COVID-19 control-patients); 21% of whom had an immunocompromising condition.
Vaccine effectiveness against COVID-19–associated hospitalization during the full surveillance period was:
- Overall = 86%
- Adults without immunocompromising conditions = 90%
- Adults with immunocompromising conditions = 63%
Effectiveness of mRNA vaccines against COVID-19–associated hospitalization was sustained over a 24-week period, including among groups at higher risk for severe COVID-19.